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Abstract
Background: Implant-based breast reconstruction (IBBR) is the most commonly performed reconstructive
procedure in the UK. The introduction of techniques to augment the subpectoral pocket has revolutionised the
procedure, but there is a lack of high-quality outcome data to describe the safety or effectiveness of these
techniques. Randomised controlled trials (RCTs) are the best way of comparing treatments, but surgical RCTs are
challenging. The iBRA (implant breast reconstruction evaluation) study aims to determine the feasibility, design
and conduct of a pragmatic RCT to examine the effectiveness of approaches to IBBR.
Methods/design: The iBRA study is a trainee-led research collaborative project with four phases:
Phase 1 – a national practice questionnaire (NPQ) to survey current practice
Phase 2 – a multi-centre prospective cohort study of patients undergoing IBBR to evaluate the clinical and
patient-reported outcomes
Phase 3– an IBBR-RCT acceptability survey and qualitative work to explore patients’ and surgeons’ views of
proposed trial designs and candidate outcomes.
Phase 4 – phases 1 to 3 will inform the design and conduct of the future RCT
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All centres offering IBBR will be encouraged to participate by the breast and plastic surgical professional
associations (Association of Breast Surgery and British Association of Plastic Reconstructive and Aesthetic Surgeons).
Data collected will inform the feasibility of undertaking an RCT by defining current practice and exploring issues
surrounding recruitment, selection of comparator arms, choice of primary outcome, sample size, selection criteria,
trial conduct, methods of data collection and feasibility of using the trainee collaborative model to recruit patients
and collect data.
Discussion: The preliminary work undertaken within the iBRA study will determine the feasibility, design and
conduct of a definitive RCT in IBBR. It will work with the trainee collaborative to build capacity by creating an
infrastructure of research-active breast and plastic surgeons which will facilitate future high-quality research that will
ultimately improve outcomes for all women seeking reconstructive surgery.
Trial registration: ISRCTN37664281
Keywords: Feasibility study, Randomised clinical trial, Breast reconstruction, Implant, ADM, Dermal sling, Methodology,
Trainee collaboratives
Background
Breast cancer affects 51,000 women each year in the
United Kingdom (UK) [1] of whom approximately 40 %
[2] will require a mastectomy. The loss of a breast may
profoundly impact women’s quality of life [3], and im-
mediate breast reconstruction (BR) is routinely offered
to improve outcomes [4].
Implant-based breast reconstruction (IBBR) is the
most commonly offered reconstructive procedure in the
UK accounting for almost 40 % of all immediate BR
performed following mastectomy for breast cancer [5].
Traditional subpectoral IBBR is performed as a two-
stage procedure. This is necessary because the subpec-
toral pocket is too small to accommodate a definitive
implant and expansion with a tissue expander is
required as a first-stage. Multiple expansions with saline,
which may be time-consuming and uncomfortable [6],
are then needed before the final implant can be inserted
at a second operation.
Over the last 10 years, the introduction of new
techniques to augment the subpectoral pocket with
biological or synthetic mesh or the patient’s own de-
epithelised skin have revolutionised the procedure. The
techniques, collectively referred to as lower-pole sling
reconstructions (LPSR), may avoid the need for a tissue
expander by facilitating single-stage direct-to-implant
reconstruction [7] and improve cosmetic outcomes
through better lower-pole projection [8–15]. Various
products are available and vary widely in cost from £200
for a synthetic mesh such as TiLOOP® [16] or TIGR®
Matrix [17] to £1900 for biological alternative [7, 18]
such as an acellular dermal matrix (e.g. Strattice® or
SurgiMend®). Product selection is currently dependent
on surgeon preference.
Despite the rapid adoption of these techniques into
routine practice, there have been no well-designed rando-
mised controlled trials (RCTs) comparing them with each
other or other BR procedures. One RCT has attempted to
compare IBBR with and without a mesh, but closed
prematurely due to poor recruitment [19]. Systematic
reviews [20–27] have summarised non-randomised stud-
ies, but these are at a high risk of bias with significant
methodological limitations and cannot be relied upon. A
more recent review [28] has critically appraised the
evidence and demonstrated a paucity of outcome data
relating to the UK practice of single-stage LPSR with non-
human biological and synthetic meshes. Comparative data
are lacking. Outcomes from UK LPSR studies, however,
suggest complication rates may exceed 30 % [29–32] com-
pared the 11 % observed with standard IBBR in the
National Mastectomy and Breast Reconstruction Audit
[33]. There is therefore a need to robustly evaluate the
outcomes of current approaches to IBBR to protect pa-
tients and provide evidence for health commissioners to
support the provision of these procedures.
Randomised clinical trials provide the best evidence for
the effectiveness of most interventions [34], but surgical
trials are complex and the challenges to the conduct of
well-designed, multi-centre RCTs are well-documented
[34–43]. Clinical trials in BR are particularly problematic
due to surgeon preference [44–55]. Over the last 20 years,
only 14 BR RCTs have been conducted [19, 55–65] of
which only four considered IBBR [19, 58, 59, 64]. System-
atic reviews [66, 67] have highlighted the need for high-
quality BR research but prevailing expert opinion suggests
that BR RCTs would be ‘unethical’, ‘impractical’ and/or ‘in-
appropriate’ [49–53]. Recent qualitative work, however,
suggests that well-designed BR RCTs that do not
compromise patient choice may be acceptable [68], but
identified a lack of understanding of pragmatic trial meth-
odology among BR surgeons as a potential barrier to trial
participation [44]. Exploratory, pre-trial work is therefore
essential to determine the feasibility of undertaking a trial
in IBBR and to inform the optimal study design.
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The paucity of data regarding the current practice and
outcomes of LPSR in the UK, however, presents particu-
lar challenges to the effective design of a pragmatic
RCT. There is insufficient data to inform the selection
of appropriate comparators, outcomes, sample size or
selection criteria. It is also unclear how many patients
may be eligible to participate. The need for high-quality
data regarding the outcomes of LPSR is increasingly
recognised [18, 69], but early progression to a poorly de-
signed trial may alienate potential participants. A large
prospective cohort study that engages surgeons, builds
collaborations, develops understanding of the need for tri-
als in IBBR and stimulates stakeholder investment in pro-
cedure evaluation while generating data to inform the
design and conduct of a future trial is therefore necessary
before a definitive pragmatic RCT can be initiated.
The National Trainee Research Collaboratives (NTRC)
have emerged over the last 5 years as a novel, but effect-
ive model for delivery of high-quality multi-centre
surgical research [70]. Originating in the West Midlands,
the general surgery collaborative network now spans the
entire UK [70] alongside subspecialist networks such as
plastic surgery [71, 72]. This innovative model of
trainees at different hospitals working together has an
impressive track record in the design and delivery of
large multi-centre cohort studies e.g. the appendicec-
tomy study which recruited 3326 patients from 95
centres over 2 months [73–75] and high-quality surgical
trials such as ROSSINI [76] (Reduction in Surgical Site
Infection using a Novel Intervention) Trial which
randomised 760 patients from 21 centres to a wound
protection device versus standard care and recruited
ahead of target. Trainees are highly motivated to partici-
pate and gain familiarity with research methodology
whilst developing practical research skills such as
recruiting patients to trials. Trainee networks have the
potential to build research capacity and make a signifi-
cant contribution to clinical research and as such are
integral to the new Royal College of Surgeons surgical
research infrastructure [70, 77]. This approach has yet to
be established in breast and reconstructive surgery but
may represent a time and cost-effective means of con-
ducting high-quality research in this area.
Methods/design
Aims
The overall aims of the iBRA (implant breast recon-
struction evaluation) study are to explore the feasibil-
ity, design and conduct of a pragmatic randomised
controlled trial (RCT) comparing the effectiveness and
cost-effectiveness of novel approaches to implant-
based breast reconstruction (IBBR) and the feasibility
of using the trainee collaborative model to deliver
such a study in breast and reconstructive surgery.
Study design
The iBRA study will have four phases:
1. Phase 1 will evaluate current practice of implant-
based breast reconstruction (IBBR) with a national
practice questionnaire (NPQ).
2. Phase 2 will prospectively examine clinical and
patient-reported outcomes (PROMs) of IBBR and
compare the outcomes of new approaches to surgery
with published quality standards [78] and outcomes
from the National Mastectomy and Breast Recon-
struction Audit (NMBRA) [5, 33, 79, 80].
3. Phase 3 will use mixed methods: an IBBR-RCT ac-
ceptability survey (IBBR-RCTAS) developed from
phases 1 and 2 and qualitative semi-structured inter-
views to explore patients’ and surgeons’ attitudes to
candidate trial designs and outcomes and their will-
ingness to participate in a future RCT.
4. Phase 4 will incorporate the findings of phases 1 to
3 to inform the design and conduct of a pragmatic
definitive RCT with an internal pilot phase which
will evaluate the effectiveness and cost-effectiveness
of two types of IBBR.
Phase 1 - National practice questionnaire (NPQ)
The aim of phase 1 is to understand current practice of
IBBR in the UK to inform the design of the definitive
RCT. This will be achieved with these objectives:
i. To establish the number of centres and surgeons
that perform IBBR and are able and willing to
participate in a future trial.
ii. To determine the incidence of each type of IBBR
being performed at centre and surgeon level
(informing trial design and sample size)
iii. To examine how surgeons select suitable patients
for surgery (informing the inclusion criteria of the
trial)
iv. To determine how the implant procedures are
performed at centre level, especially how lower-pole
coverage is achieved (informing trial design)
v. To establish current practice of pre and post-
surgical care in IBBR which will inform the use and
standardisation of concomitant interventions in the
trial
vi. To engage surgeons to develop an appreciation of
the need for RCTs in IBBR
Development of the National Practice Questionnaire
The questionnaire will be developed by members of the
steering group. It will ask each centre for information on
current IBBR practice (operations and approaches), the
multi-disciplinary team in the unit (the type of staff and
numbers), the use of novel techniques (dermal slings,
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biological and synthetic meshes and products used) and
how patients are selected for procedure types (the role
of neoadjuvant treatments, diabetes, smoking and body
habitus). Information about the care pathway in each
centre will also be collected.
Inclusion criteria for the NPQ
All breast and plastic surgical units performing mastec-
tomy with or without BR in women in the UK will be
eligible for inclusion.
Data collection in each participating centre
Trainees will be invited by e-mail to participate in the
study through the Mammary Fold (MF) Breast Trainees’
Association, the National Trainee Research Collaborative
(NTRC) and the Reconstructive Surgery Trials Network
(RSTN). Trainees willing to act as the trainee lead for
their centre will be asked to contact the study team to
express their willingness to participate and to register
their Unit. Unit participation and Trainee Lead status
will then be confirmed by the study team and relevant
documentation sent. Follow-up e-mails will be sent via
the MF, RSTN and the professional associations to
encourage study participation. Trainee leads will be
responsible for identifying a supervising consultant and
obtaining the support of other consultants in the Unit.
This is the standard approach for NTRC projects which
is acceptable and highly effective.
Local Trainee Leads will be responsible for completing
the NPQ, paper-based or electronically, with the support
of their supervising consultants.
The professional associations (Association of Breast
Surgery, ABS and British Association of Plastic, Recon-
structive and Aesthetic Surgeons, BAPRAS) have
endorsed the study and will encourage Units to partici-
pate and support their trainees in recruiting patients and
collecting data.
Sample size
The National Mastectomy and Breast Reconstruction
Audit (NMBRA) [33] collected data from 156 acute
Trusts performing mastectomy and BR surgery.
Based on a 60 % participation rate, it is anticipated
that 100 units may contribute to the study. The
study team will approach breast and plastic surgical
units via both trainees and the professional associa-
tions to maximise participation.
Questionnaire data analysis
Questionnaire data will be summarised and summary
statistics reported to describe provision of care and
practice of IBBR.
Categorical data will be summarised by counts and
percentages. Continuous data will be summarised by
mean, standard deviation and range if data is normally
distributed. Median, interquartile range and range will
be reported if the data is skewed. No formal statistical
testing will be undertaken.
Where respondents’ free-text responses have been
collected these will be anonymised. Thematic analysis
will be performed and results presented alongside the
quantitative analysis to help contextualise and illu-
minate them.
Feedback and surgeon engagement
Participating units will receive individualised feedback
via reports giving their responses alongside cohort
averages and national quality standards. This will
highlight variation between local and regional practice
and enable surgeons and units to compare their local
practice to regional and national standards. It will also
engage them in the project and highlight the need for
a RCT to generate evidence-based practice for re-
gional consistency.
Phase 2 - Prospective cohort study of patients
undergoing implant-based breast reconstruction
The aim of phase 2 is to document the practice and
outcomes of IBBR in the UK to inform the design of
a definitive RCT. This will be achieved with these
objectives:
i. To determine variation in the types of implant-based
procedures performed at centre level, in particular,
variation in techniques used to achieve lower-pole
cover (informing trial design).
ii. To evaluate the practicality of obtaining clinical and
patient-reported outcome data across centres with
little or no experience in participating in surgical
trials, including the feasibility of working with
trainees to recruit patients and collect longitudinal
data (modelling this on experience in general surgi-
cal collaboratives [76]), with a view to using this
approach in a future trial.
iii. To compare the outcomes of different approaches of
IBBR to published clinical standards and identify risk
factors associated with adverse outcomes such as the
impact of the learning curve (informing entry
criteria, primary and secondary outcomes and
parameters required for a power calculation).
iv. To explore the variability of the BREAST-Q between
procedure subtypes and hence its value for use in a
future trial.
v. To engage and educate consultants and trainees
through regular feedback to create a culture of
collaborative working and to establish an
appreciation of the need for, and a desire to
participate in, a future trial in IBBR.
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vi. To create the infrastructure to deliver a future trial
by developing a network of breast and plastic
surgical trainees trained in research methodology
supported by consultant surgeons who will
participate and recruit patients to surgical trials.
Methodology
Centres identified as performing immediate IBBR from
the NPQ (phase 1) will be eligible to progress to phase
2, the prospective cohort study. The named supervising
consultant will act as the principal investigator for each
unit and trainee leads will be responsible for recruitment
and data collection.
The study will be piloted in two centres (Liverpool
and Bristol) prior to national roll-out to evaluate feasibil-
ity and effectiveness of trainee involvement in recruit-
ment and data collection. Methods of data management
will also be assessed.
Patient inclusion and exclusion criteria
All female patients electing to undergo immediate IBBR
for malignancy or risk-reduction under the care of the
breast or plastic surgeons will be eligible for inclusion in
the study. Excluded will be women undergoing delayed
IBBR, revisional surgery and those not able or willing to
provide written consent (for patient-reported outcome
measures (PROMs) part of the study).
Participation identification and recruitment
Potential participants will be identified prospectively by
the local study team via clinics, local multi-disciplinary
team meetings (MDTs), consultant surgeons and clinical
nurse specialists. Simple demographics, procedure and
process data will be collected for each participant. Data
will be recorded in an anonymised format using a
unique alphanumeric study identification number on
a secure web-based database. In-hospital complication
data will be collected prospectively by trainee leads.
Patients will be reviewed in clinics at 30 days to col-
lect complication and oncology data. Note that review
will be performed in patients who do not attend for
30 day follow-up.
Trainees or a locally designated member of the team
will approach patients in clinics or during their admis-
sion to obtain consent for PROMs assessment. Individ-
ual centres will be free to determine the optimal
approach for recruiting patients to this part of the study.
PROMs assessment will be by post or e-mail, dependent
on patient preference, at 3 and 18 months (for those
eligible for long-term assessment) following surgery and
will evaluate satisfaction with care, complications and
health-related quality of life (see details below). If con-
sent is obtained, contact details will be sent securely to
the co-ordinating centre and questionnaires distributed
centrally to optimise compliance, allow accurate follow-
up and reduce the incidence of missing data.
Sample size considerations
This feasibility study aims to estimate parameters
required for an RCT sample size calculation although
the primary outcome most suitable is not yet known.
Parameters include estimating the standard deviations
for each candidate outcome listed below from which, as
a result of this study, the most important outcome will
be determined and used as the primary outcome when
progressing to an RCT.
To inform the assessment of long-term outcomes, 65
patients will be followed-up for a period of 18 months.
Allowing for an estimated 20 % loss to follow-up rate (as
observed in the National Mastectomy and Breast Recon-
struction Audit, NMBRA), long-term data will be
collected from approximately 50 patients. This is
sufficient to give a reasonable estimate of the standard
deviation of the BREAST-Q assessment.
Over the first 12–15 months of the study, the team
will aim to recruit as many patients as possible and
follow all up to 3 months to estimate with reasonable
precision the incidence of each short-term outcome
within different treatment approaches. To illustrate, the
NMBRA observed an implant loss rate of 9 % in IBBR
patients at 3 months. Should this be chosen as the
primary outcome in the full trial, establishing this
proportion with reasonable precision is vital for the
sample size calculation. Using the large sample normal
approximation, a sample size of 197 would result in the
two-sided 95.0 % confidence interval for a single propor-
tion, assumed to be 0.09, extending from 0.05 to 0.13.
Allowing for the 15 % loss to follow-up at 3 months
reported in the NMBRA, analysis of implant loss at
3 months would require at least 235 patients to be
recruited. Each unit will perform a relatively small num-
ber of procedures (4–40 per year) and so the study team
will aim to recruit within at least 20 sites.
Study outcomes
Currently, it is likely that the primary outcome of the
main trial will be based on a clinical effectiveness end-
point. This is likely to be one of the outcomes from the
recently developed reconstructive breast surgery core
outcome set (RBS-COS) [81]. The study management
group is currently considering candidate measures
below—these will be monitored in phase 2 in terms of
data quality to inform the main trial.
 Implant loss: Unplanned and unexpected extirpation
or loss of the implant including removal as a result
of infection; failure of the reconstruction in the 3 or
18 months following surgery.
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 Infection: a hot, red swollen breast associated with
one of the following: a temperature, pus at the
wound site, a raised white cell count or a positive
wound culture in the 3 months following surgery.
These are important as they may lead to implant
loss and reconstructive failure.
 Major complications: as defined by the RBS-COS:
Any adverse event that requires return to the
operating theatre or readmission to hospital for any
complication related to the reconstruction during
the first 3 months following surgery. These include
admission for intravenous antibiotics for a wound
infection or debridement of skin necrosis and are
hypothesised to adversely impact the outcome of the
reconstruction.
 Patient satisfaction with the outcome of IBBR as
assessed using the BREAST-Q questionnaire at
18 months following surgery.
Additional outcomes of interest from the RBS-COS
include quality of life, normality, self-esteem, emotional
well-being and physical well-being and will be assessed
at 18 months following surgery using the validated
BREAST-Q questionnaire [82, 83].
Analysis
Clinical outcomes Simple summary statistics will be
calculated to describe demographic, procedure,
process and outcome data overall and at a site level.
Categorical data will be summarised by counts and
percentages. Continuous data will be summarised by
mean, standard deviation and range if data is normally
distributed. Median, interquartile range and range will
be reported if the data is skewed. No formal statistical
testing will be undertaken.
Patient-reported outcome measures – 3 and 18 months
Simple summary statistics will be calculated to de-
scribe the parameters identified in the PROMs at 3
and 18 months, and to estimate the variability in
outcome in order to determine sample size for the
future trial.
Modules from the BREAST-Q questionnaire (Satisfac-
tion with Breast, Satisfaction with Outcome, Psycho-
social Well-being; Sexual Well-being; Physical Well-
being) will be analysed using the BREAST-Q-specific
analysis package and data managed according to
BREAST-Q guidelines.
It is anticipated that women undergoing the novel
approaches to IBBR will report higher functioning in all
domains as a result of having undergone a single versus
two-stage procedure with potentially improved cosmetic
outcomes. The discriminatory value of the BREAST-Q
in detecting differences between procedure subtypes will
be explored to determine the benefit of using the
BREAST-Q for PROMs assessment in the main trial.
Exploratory analysis A key aim of this study is to de-
termine trial comparators for an RCT. Interventions
considered to be prominent are variations in surgical
techniques: sub-muscular placement, dermal slings,
biological and synthetic meshes. The impact of sub-
types of these comparators on the outcomes of inter-
est will be considered.
It is hypothesised that several risk factors may increase
the likelihood of an adverse event. Exploratory analysis
will help determine best practice to minimise adverse
outcomes in the main study.
Feedback and surgeon engagement
Individual units will receive anonymised feedback in the
form of a report to illustrate variation between local
outcomes (clinical and PROMs) and the national stand-
ard and outcomes of different procedure subtypes
overall. This will be used to highlight variations in the
outcomes of IBBR and the need for an RCT to generate
evidence-based practice.
Phase 3 – Using mixed methods to explore the acceptability
of proposed trial designs to patients and surgeons
The aim of phase 3 is to use mixed methods (a ques-
tionnaire survey and semi-structured qualitative inter-
views) to investigate the acceptability to patients and
surgeons of candidate trial designs generated from
phases 1 and 2 to determine a suitable design to pro-
gress to a definitive, pragmatic trial. This will be
achieved with these objectives:
i. To determine the proportion of patients and
surgeons willing and able to participate in each
candidate study design
ii. To determine patients’ and surgeons’ views
regarding the most appropriate primary outcome for
the definitive trial
iii. To determine the degree of pragmatism (e.g.
product selection; technique; variation in pre/peri/
post-operative care) that would be feasible and
acceptable to surgeons in the definitive trial
iv. To explore barriers and facilitators to potential
participation in an RCT in IBBR and how these
challenges may be overcome.
Methodology
Randomisation acceptability survey Using phase 1 and
2 data, two RCT acceptability surveys (RCTAS) (one
each for patients and surgeons) will be developed by
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members of the steering group. Respondents will
communicate their willingness to participate in different
candidate trials, give opinions regarding primary
outcomes and surgeons will offer views about the degree
of pragmatism that would be acceptable in a future trial.
Participant identification and inclusion criteria
All patients and surgeons who participated in earlier
phases will be invited to complete the IBBR-RCTAS by
post or online.
Analysis
Survey items will be summarised both overall and split
by patient and surgeon-respondent groups.
Categorical data will be summarised by counts and
percentages. Continuous data will be summarised by
mean, standard deviation and range if data is normally
distributed. Median, interquartile range and range will
be reported if the data is skewed. No formal statistical
testing will be undertaken.
Free-text responses will be anonymised and analysed
thematically. Findings will be summarised in descriptive
accounts supporting conclusions with illustrative quotes.
Results will be presented alongside the questionnaire
findings to help contextualise and illuminate them.
Semi-structured qualitative interviews
Semi-structured qualitative interviews will be used to ex-
pand on findings from the questionnaire survey and pro-
vide an in-depth exploration of the acceptability of
proposed trial designs.
Participant identification and sampling
Respondents to the questionnaire who are willing to be
contacted will be purposively sampled and interviewed
to explore common and unusual questionnaire
responses to enable a more detailed understanding of
the acceptability of proposed study designs. Patients and
surgeons will be interviewed (with the final number
depending on data saturation) using a flexible topic
guide to investigate their views on willingness to partici-
pate in the proposed study designs, appropriate outcome
measures and, for surgeons, the degree of pragmatism
that would be acceptable and feasible in the definitive
trial. Interviews will be audio-recorded, with consent,
and fully transcribed.
Analysis
Analysis will be an ongoing and iterative process com-
mencing soon after data collection. Transcripts will be
imported into the qualitative data analysis software NVivo
where they will be systematically assigned codes and ana-
lysed thematically to identify key categories using tech-
niques of constant comparison. Preliminary analysis of
early interviews will be used to inform further data
collection and analysis. A second member of the team, an
experienced social scientist (NM), will independently
analyse a proportion of transcripts to assess the depend-
ability of coding, and will meet regularly to review coding
and descriptive findings, agree further sampling strategies
and discuss findings in light of the interview and question-
naire data.
Data management
Study data will be collected and managed using REDCap
electronic data capture tools hosted at University of
Edinburgh. REDCap [84] (Research Electronic Data
Capture) is a secure, web-based application designed to
support data capture for research studies, providing (1)
an intuitive interface for validated data entry, (2) audit
trails for tracking data manipulation and export proce-
dures, (3) automated export procedures for seamless
data downloads to common statistical packages, and (4)
procedures for importing data from external sources.
Criteria for determining progression to main trial design
The feasibility study will determine the most appropriate
study design. The primary outcome will be identified,
and outcome data used to inform a sample size calcula-
tion. Information from rates of surgery and patient se-
lection criteria will be combined with estimates of
surgeon and centre willingness to participate in a trial to
assess the feasibility of undertaking a definitive trial that
would achieve target recruitment within 3 years.
The following specific progression criteria will be
reviewed at 30 months:
1. At least 40 % of surgeons and patients responding to
the RCT acceptability survey can agree to participate
in an RCT in implant-based breast reconstruction
surgery
2. The cohort study data and findings of the RCT
acceptability surveys (for patients and surgeons) and
qualitative work provide sufficient information to
inform the selection of an acceptable and
appropriate primary outcome measure to inform the
sample size required for main study.
3. Based on the sample size calculation for the chosen
primary outcome, the number of centres willing to
participate, the anticipated patient consent rate, and
data from the incident numbers of patients that are
likely to be eligible to participate in a RCT, including
information about reconstructive techniques used
and to be compared in the trial, the study will be
practical and achievable with three years of
recruitment. Data from an analysis of NIHR
portfolio data (Kaur, MRC North West Hub for
Trials Methodology Research, personal
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communication) shows that the trials recruiting to
time and target did so with a median recruitment
period of 13 months, interquartile range 8 to 24. 42/
45 (93 %) recruited successfully within 3 years.
Although these data are for paediatric trials, there is
no obvious reason why the results would not be
generalisable to recruitment in adult studies.
4. Data from the surveys show that a sufficient number
of centres, each with a minimum of two
participating surgeons are willing and able to
participate in the main trial.
5. Feasibility of using the trainee collaborative model to
recruit patients and follow them up with <10 %
missing data over all the specified time points.
If all points are satisfied, then an application for the
main trial using the trainee collaborative model will be
made; however, if only points 1–4 are satisfied, then the
application will include costings for research nurses to
recruit and follow up patients.
It is anticipated that the definitive RCT will compare
the effectiveness and cost-effectiveness of two subtypes
of single-stage IBBR. It will be large-scale and reflect
current practice as determined in the feasibility study. It
will be designed with an internal pilot phase which will
test whether randomisation is acceptable to patients and
surgeons and ensure the processes required for the main
trial work together.
Study governance and consent to participate
Ethical approval is not required for phases 1 and 2
because they involve the routine collection of clinical
and patient-reported outcome data as recommended by
‘Oncoplastic Surgery: Guidelines for Good Practice [78]’.
Established quality standards for the candidate outcomes
have been published [78] and outcomes will be
compared to these standards.
Participating centres will therefore be requested to regis-
ter the study with their clinical audit departments and
obtain patient consent for the distribution of patient-
reported outcome questionnaires at 3 and 18 months as
per previous national studies [79, 85].
Proportional ethics review will be obtained prior to
commencing Phase 3, the mixed methods study as this
will involve surveying and interviewing patients and
professionals regarding the acceptability of a future RCT
in IBBR.
Discussion
The practice of implant-based breast reconstruction has
changed dramatically over the last 10 years, but there is a
lack of high-quality evidence to support the safety or ef-
fectiveness of the new techniques [28]. Randomised trials
are needed but the challenges to the successful conduct of
surgical trials, and particularly those in reconstructive
breast surgery, are well-established [37]. The iBRA study
will explore the feasibility of undertaking a large-scale
randomised clinical trial in implant-based breast
reconstruction. It will use mixed methods to explore the
acceptability of candidate comparators and other key trial
elements such as primary and secondary outcomes such
that the optimal trial design is established. The study will
also inform other important design issues including the
degree of pragmatism that participating surgeons would
find acceptable and determine which concomitant inter-
ventions would be permitted within the trial. It is hoped
that the iBRA study will lead to the design of a definitive
pragmatic multi-centre RCT with an internal pilot phase
to explore recruitment issues which will address the
clinical and cost-effectiveness of new approaches to IBBR.
If a trial is not found to be feasible, the iBRA study
will still be of significant value to patients and profes-
sionals as it will represent the largest prospective cohort
study of new approaches to IBBR to date. This will
provide high-quality observational data to inform
decision making for patients and surgeons. The study
will also provide a powerful dataset which will allow
potential predictors of adverse outcome to be explored.
This may inform best practice, lead to the generation of
new guidelines and generate hypotheses that will lead to
future work in this area. Identification of variations in
practice and outcomes may also promote better stand-
ardisation of care and improve outcomes for patients
considering surgery in the future. Finally, the study will
provide a further data cycle following the National
Mastectomy and Breast Reconstruction Audit [5, 33, 79,
80] to demonstrate whether outcomes for women under-
going IBBR have improved. If they have not, this will
focus the attention of the breast community on relevant
areas and highlight the need for future research.
The iBRA study represents the first time that trainee
collaborative methodology has been applied to breast
and reconstructive surgery and the first time that breast
and plastic surgeons have worked together in this way. It
is anticipated that the successful conduct of the study
will create research capacity by developing a network of
trainees and consultants trained in research method-
ology who will be willing and able to recruit patients to
trials and deliver future high-quality research in breast
and reconstructive surgery. This will improve the quality
and quantity of breast surgical trials and ultimately
improve outcomes for patients.
Study status
Data collection for phase 1 of the iBRA study is now
complete with 81 units completing the NPQ. The pilot
study was successful and phase 2, the prospective cohort
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study is currently underway with the first patient re-
cruited to the main study in April 2014. Sixty-five units
are currently recruiting to the study and recruitment is
ahead of schedule. It is anticipated that recruitment to
phase 2 will continue until June 2016.
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